Alamar Biosciences to Participate in Morgan Stanley 24th Annual Global Healthcare Conference
Rhea-AI Summary
Alamar Biosciences (Nasdaq: ALMR) announced that its management will participate in the Morgan Stanley 24th Annual Global Healthcare Conference in New York, NY. The company is scheduled for a fireside chat on Tuesday, September 15, at 4:05 p.m. Eastern Time, with live and archived webcasts available via its investors website.
Positive
- None.
Negative
- None.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Aug 10 | Quarterly earnings | Positive | +30.6% | Strong revenue growth and 2026 guidance accompanied expanded operating losses. |
| Aug 10 | Partnership expansion | Positive | +30.6% | Expanded Alzheimer’s research partnership added 86,000 plasma samples to the program. |
| Jul 28 | Product launch | Positive | -1.4% | Immune 340 Panel launch expanded multiplexed immune profiling capabilities for research applications. |
| Jul 14 | Earnings scheduling | Neutral | -3.4% | Company scheduled second-quarter financial results and an accompanying webcast for August 10. |
| Jul 13 | Research partnership | Positive | -3.6% | National initiative planned proteomic profiling of approximately 21,000 Alzheimer’s research samples. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Positive announcements showed mixed reactions: two aligned with gains, while three diverged with declines.
Key Terms
precision proteomics technical
AI-generated analysis. How Rhea-AI works. Not financial advice.
FREMONT, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Alamar Biosciences, Inc. (Nasdaq: ALMR), a leader in precision proteomics dedicated to enabling the earliest detection of disease, today announced the company will be participating in the upcoming Morgan Stanley 24th Annual Global Healthcare Conference in New York, NY.
Alamar Biosciences’ management is scheduled to participate in a fireside chat on Tuesday, September 15, at 4:05 p.m. Eastern Time. Interested parties may access a live and archived webcast of the session on the “Investors” section of the company website at investors.alamarbio.com.
About Alamar Biosciences, Inc.
Alamar is a commercial-stage proteomics company establishing a gold standard in protein detection and analysis. Leveraging our proprietary NULISA™ technology and the ARGO™ HT System, our platform is designed to detect protein biomarkers at extremely low concentrations in blood with ultra-high sensitivity, high specificity, flexible multiplexing, broad dynamic range and seamless automation. We refer to this combination of features as “Precision Proteomics,” and believe it fills a critical gap in the field of advanced proteomics, helping researchers unlock the full spectrum of protein biomarkers across disease states. Learn more at alamarbio.com.
Investor contact:
Media contact:
